MCID: DMN002
MIFTS: 72

Dementia

Categories: Mental diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Dementia

MalaCards integrated aliases for Dementia:

Name: Dementia 11 52 75 28 53 5 41 43 14 38 71 33
Mental and Behavioural Disorders Due to Use of Sedatives or Hypnotics, Residual and Late-Onset Psychotic Disorder 33
Primary Degenerative Alzheimer Type Dementia, Presenile Onset, Uncomplicated 33
Hiv- [human Immunodeficiency Virus] Associated Cognitive Motor Complex 33
Hiv- [human Immunodeficiency Virus] Associated Dementia Complex 33
Late-Onset Psychoactive Substance-Induced Psychotic Disorder 33
Aids - [acquired Immunodeficiency Syndrome] Dementia Complex 33
Residual and Late-Onset Alcohol-Induced Psychotic Disorder 33
Primary Degenerative Alzheimer Type Dementia, Early Onset 33
Primary Degenerative Alzheimer Type Dementia, Late Onset 33
Senile Primary Degenerative Alzheimer Type Dementia 33
Early Onset Alzheimer Type Dementia, Uncomplicated 33
Dementia in Alzheimer Disease with Early Onset 33
Sdlt - [senile Dementia of the Lewy Body Type] 33
Dementia in Alzheimer Disease with Late Onset 33
Hiv - [human Immunodeficiency Virus] Dementia 33
Primary Degenerative Alzheimer Type Dementia 33
Alzheimer Disease Dementia with Early Onset 33
Alzheimer Disease Dementia with Late Onset 33
Sdat - [senile Dementia, Alzheimer Type] 33
Dementia Syndrome of Parkinson Disease 33
Senile Dementia of the Lewy Body Type 33
Senile Dementia of the Alzheimer Type 33
Dementia in Alzheimer Disease Type 2 33
Dementia in Alzheimer Disease Type 1 33
Late Onset Alzheimer Brain Sclerosis 33
Presenile Alzheimer Brain Sclerosis 33
Alzheimer's Type Atypical Dementia 33
Pdd - [parkinson Disease Dementia] 33
Alzheimer Type Presenile Dementia 33
Dementia Due to Niacin Deficiency 33
Senile Alzheimer Brain Sclerosis 33
Chronic Alcoholic Brain Syndrome 33
Dementia of the Lewy Body Type 33
End Stage Alzheimer's Dementia 33
Early Onset Alzheimer Dementia 33
Senile Alzheimer Brain Disease 33
Late Onset Alcoholic Psychosis 33
Late Onset Alzheimer Dementia 33
Vascular Cognitive Impairment 33
Dementia in Paralysis Agitans 33
Dementia in Parkinson Disease 33
Dementia in Huntington Chorea 33
Alzheimer Disease Dementia 33
Strategic-Infarct Dementia 33
Volatile Solvents Dementia 33
Parkinson Related Dementia 33
Dementia with Lewy Bodies 33
Presenile Brain Sclerosis 33
Arteriosclerotic Dementia 33
Alcohol-Related Dementia 33
Alcohol-Induced Dementia 33
Alcoholic Brain Syndrome 33
Alzheimer Type Dementia 33
Alcoholic Dementia Nos 33
Aids Related Dementia 33
Post Stroke Dementia 33
Alzheimer Sclerosis 33
Presenile Sclerosis 33
Alzheimer Dementia 33
Presenile Dementia 71
Vascular Dementia 33
Inhalant Dementia 33
Alcohol Dementia 33
Dementias 14

Classifications:



Summaries for Dementia

MedlinePlus: 41 What is dementia? Dementia is a loss of mental functions that is severe enough to affect your daily life and activities. These functions include: Memory Language skills Visual perception (your ability to make sense of what you see) Problem solving Trouble with everyday tasks The ability to focus and pay attention It is normal to become a bit more forgetful as you age. But dementia is not a normal part of aging. It is a serious disorder which interferes with your daily life. What are the types of dementia? The most common types of dementia are known as neurodegenerative disorders. These are diseases in which the cells of the brain stop working or die. They include: Alzheimer's disease, which is the most common form of dementia among older people. People with Alzheimer's have plaques and tangles in their brain. These are abnormal buildups of different proteins. Beta-amyloid protein clumps up and forms plaques in between your brain cells. Tau protein builds up and forms tangles inside the nerve cells of your brain. There is also a loss of connection between nerve cells in the brain. Lewy body dementia, which causes movement symptoms along with dementia. Lewy bodies are abnormal deposits of a protein in the brain. Frontotemporal disorders, which cause changes to certain parts of the brain: Changes in the frontal lobe lead to behavioral symptoms Changes in the temporal lobe lead to language and emotional disorders Vascular dementia, which involves changes to the brain's blood supply. It is often caused by a stroke or atherosclerosis (hardening of the arteries) in the brain. Mixed dementia, which is a combination of two or more types of dementia. For example, some people have both Alzheimer's disease and vascular dementia. Other conditions can cause dementia or dementia-like symptoms, including: Creutzfeldt-Jakob disease, a rare brain disorder Huntington's disease, an inherited, progressive brain disease Chronic traumatic encephalopathy (CTE), caused by repeated traumatic brain injury HIV-associated dementia (HAD) Who is at risk for dementia? Certain factors can raise your risk for developing dementia, including: Aging. This is the biggest risk factor for dementia. Smoking Uncontrolled diabetes High blood pressure Drinking too much alcohol Having close family members who have dementia What are the symptoms of dementia? The symptoms of dementia can vary, depending on which parts of the brain are affected. Often, forgetfulness is the first symptom. Dementia also causes problems with the ability to think, problem solve, and reason. For example, people with dementia may: Get lost in a familiar neighborhood Use unusual words to refer to familiar objects Forget the name of a close family member or friend Forget old memories Need help doing tasks that they used to do by themselves Some people with dementia cannot control their emotions and their personalities may change. They may become apathetic, meaning that they are no longer interested in normal daily activities or events. They may lose their inhibitions and stop caring about other peoples' feelings. Certain types of dementia can also cause problems with balance and movement. The stages of dementia range from mild to severe. In the mildest stage, it is just beginning to affect a person's functioning. In the most severe stage, the person is completely dependent on others for care. How is dementia diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam Tests of your thinking, memory, and language abilities Other tests, such as blood tests, genetic tests, and brain scans A mental health evaluation to see whether a mental disorder is contributing to your symptoms What are the treatments for dementia? There is no cure for most types of dementia, including Alzheimer's disease and Lewy body dementia. Treatments may help to maintain mental function longer, manage behavioral symptoms, and slow down the symptoms of disease. They may include: Medicines may temporarily improve memory and thinking or slow down their decline. They only work in some people. Other medicines can treat symptoms such as anxiety, depression, sleep problems, and muscle stiffness. Some of these medicines can cause strong side effects in people with dementia. It is important to talk to your health care provider about which medicines will be safe for you. Occupational therapy to help find ways to more easily do everyday activities Speech therapy to help with swallowing difficulties and trouble speaking loudly and clearly Mental health counseling to help people with dementia and their families learn how to manage difficult emotions and behaviors. It can also help them plan for the future. Music or art therapy to reduce anxiety and improve well-being Can dementia be prevented? Researchers have not found a proven way to prevent dementia. Living a healthy lifestyle might influence some of your risk factors for dementia.

MalaCards based summary: Dementia, also known as mental and behavioural disorders due to use of sedatives or hypnotics, residual and late-onset psychotic disorder, is related to dementia, lewy body and frontotemporal dementia, and has symptoms including tremor, back pain and angina pectoris. An important gene associated with Dementia is PSEN1 (Presenilin 1), and among its related pathways/superpathways are Alzheimer's disease and miRNA effects and Neuroscience. The drugs Sevoflurane and Propofol have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and bone marrow, and related phenotypes are nervous system and homeostasis/metabolism

NINDS: 52 Dementia is the loss of cognitive functioning—the ability to think, remember, problem solve or reason—to such an extent that it interferes with a person’s daily life and activities. Dementia ranges in severity from the mildest stage, when it is just beginning to affect a person’s functioning, to the most severe stage, when the person must depend completely on others for basic activities of daily living. Functions affected include memory, language skills, visual perception, problem solving, self-management, and the ability to focus and pay attention. Some people with dementia cannot control their emotions, and their personalities may change. Signs and symptoms of dementia result when once-healthy neurons (nerve cells) in the brain stop working, lose connections with other brain cells, and die. While everyone loses some neurons as they age, people with dementia experience far greater loss. Unlike dementia, age-related memory loss isn’t disabling. While dementia is more common with advanced age (as many as half of all people age 85 or older may have some form of dementia), it is not normal part of aging. Many people live into their 90s and beyond without any signs of dementia. The causes of dementia can vary. Many people with dementia have both Alzheimer’s disease and one or more closely related disorders that share brain scanning or clinical (and sometimes both) features with Alzheimer’s disease. When a person is affected by more than one dementia disorder, the dementia can be referred to as a mixed dementia. Some people may have mixed dementia caused by Alzheimer’s-related neurodegenerative processes, vascular disease-related processes, or another neurodegenerative condition. Many other conditions such as Creutzfeldt-Jakob disease, Huntington’s Disease, and chronic traumatic encephalopathy can cause dementia or dementia-like symptoms. Risk factors for dementia include advancing age, stroke, high blood pressure, poorly controlled diabetes, and a thickening of blood vessel walls (atherosclerosis). Other dementias include frontotemporal disorders, vascular dementia, and Lewy body dementia.

Disease Ontology: 11 A cognitive disorder resulting from a loss of brain function affecting memory, thinking, language, judgement and behavior.

Wikipedia: 75 Dementia is a disorder which manifests as a set of related symptoms, which usually surfaces when the... more...

Related Diseases for Dementia

Diseases in the Dementia family:

Rare Dementia Infectious Disease with Dementia

Diseases related to Dementia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1806)
# Related Disease Score Top Affiliating Genes
1 dementia, lewy body 33.9 VCP TREM2 SNCB SNCA PSEN2 PSEN1
2 frontotemporal dementia 33.9 VCP TYROBP TREM2 SNCB SNCA SERPINI1
3 alzheimer disease, familial, 1 33.7 VCP TREM2 SNCB SNCA SERPINI1 PSEN2
4 vascular dementia 33.6 SNCA PSEN2 PSEN1 PRNP NOTCH3 MAPT
5 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 33.5 VCP SNCA PSEN1 MAPT GRN CHCHD10
6 pick disease of brain 33.5 VCP TREM2 SNCB SNCA PSEN2 PSEN1
7 inclusion body myopathy with paget disease of bone and frontotemporal dementia 33.4 VCP MAPT GRN CHCHD10 C9orf72
8 binswanger's disease 33.3 NOTCH3 MAPT APP APOE
9 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 33.3 SNCA MAPT C9orf72
10 frontotemporal dementia and/or amyotrophic lateral sclerosis 7 33.3 VCP MAPT GRN
11 cerebral amyloid angiopathy, itm2b-related, 1 33.3 SERPINI1 PSEN2 PSEN1 PRNP ITM2B APP
12 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 33.3 PRNP MAPT GRN
13 polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1 33.3 TYROBP TREM2 PSEN2 PSEN1 GRN APP
14 amyotrophic lateral sclerosis 1 33.3 VCP TYROBP TREM2 SNCA PSEN2 PSEN1
15 gerstmann-straussler disease 33.2 SNCA PSEN2 PSEN1 PRNP MAPT APP
16 mild cognitive impairment 33.1 TREM2 SNCA PSEN2 PSEN1 MAPT BDNF
17 creutzfeldt-jakob disease 33.0 SNCA PSEN1 PRNP MAPT C9orf72 APP
18 leukoencephalopathy, hereditary diffuse, with spheroids 1 33.0 TYROBP TREM2 NOTCH3 GRN C9orf72
19 parkinson disease, late-onset 33.0 VCP SNCB SNCA PSEN2 PSEN1 PRNP
20 frontotemporal dementia and/or amyotrophic lateral sclerosis 3 32.9 CHCHD10 C9orf72
21 cerebral amyloid angiopathy, app-related 32.9 PSEN2 PSEN1 ITM2B APP APOE
22 parkinsonism 32.9 SNCB SNCA PSEN1 MAPT GRN GBA1
23 aphasia 32.8 VCP SNCB SNCA PSEN2 PSEN1 PRNP
24 supranuclear palsy, progressive, 1 32.8 VCP TREM2 SNCA PSEN2 PSEN1 PRNP
25 frontotemporal dementia and/or amyotrophic lateral sclerosis 4 32.8 CHCHD10 C9orf72
26 frontotemporal dementia and/or amyotrophic lateral sclerosis 2 32.8 CHCHD10 C9orf72
27 kufor-rakeb syndrome 32.8 SNCA GBA1 ATP13A2
28 huntington disease 32.7 SNCA SERPINI1 PSEN2 PSEN1 PRNP MAPT
29 cerebral amyloid angiopathy, cst3-related 32.7 TREM2 SNCA PSEN2 PSEN1 PRNP NOTCH3
30 inclusion body myopathy with early-onset paget disease of bone with or without frontotemporal dementia 2 32.6 VCP MAPT C9orf72
31 progressive non-fluent aphasia 32.5 VCP TREM2 PSEN1 MAPT GRN C9orf72
32 motor neuron disease 32.5 VCP SNCA MAPT GRN CHCHD10 C9orf72
33 prion disease 32.5 SNCA PSEN2 PSEN1 PRNP MAPT APP
34 down syndrome 32.5 PSEN1 MAPT BDNF APP APOE
35 fatal familial insomnia 32.4 SNCA PSEN2 PSEN1 PRNP MAPT C9orf72
36 normal pressure hydrocephalus 32.4 SNCA PSEN2 PSEN1 MAPT APP APOE
37 cerebrovascular disease 32.4 NOTCH3 MAPT BDNF APP APOE
38 schizophrenia 32.4 SNCA PSEN1 MAPT C9orf72 BDNF APP
39 spinocerebellar ataxia 2 32.4 VCP CHCHD10 C9orf72
40 amyotrophic lateral sclerosis type 14 32.3 VCP CHCHD10 C9orf72
41 amyloidosis 32.3 SNCA PSEN2 PSEN1 PRNP MAPT ITM2B
42 multiple system atrophy 1 32.3 SNCB SNCA PRNP MAPT GBA1 C9orf72
43 anosognosia 32.3 PSEN2 PSEN1 MAPT C9orf72 APOE
44 neuronal ceroid lipofuscinosis 32.2 VCP SNCA PSEN1 MAPT GRN GBA1
45 amyloidosis, hereditary, transthyretin-related 32.2 SNCA APP APOE
46 alzheimer disease 19 32.2 PSEN2 PSEN1 APP APOE
47 spinocerebellar ataxia 1 32.2 SNCA C9orf72 APP
48 alzheimer disease 2 32.1 SNCA APP APOE
49 alzheimer disease 3 32.1 PSEN2 PSEN1 APP APOE
50 parkinson disease 1, autosomal dominant 32.1 SNCA GBA1

Graphical network of the top 20 diseases related to Dementia:



Diseases related to Dementia

Symptoms & Phenotypes for Dementia

UMLS symptoms related to Dementia:


tremor; back pain; angina pectoris; headache; syncope; pain; chronic pain; sciatica; seizures; vertigo/dizziness; equilibration disorder; sleeplessness

GenomeRNAi Phenotypes related to Dementia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.14 APOE APP ATP13A2 BDNF C9orf72 CHCHD10
2 no effect GR00402-S-2 10.14 APOE APP BDNF C9orf72 ITM2B NOTCH3

MGI Mouse Phenotypes related to Dementia:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.54 APOE APP ATP13A2 BDNF C9orf72 CHCHD10
2 homeostasis/metabolism MP:0005376 10.49 APOE APP ATP13A2 BDNF C9orf72 CHCHD10
3 growth/size/body region MP:0005378 10.43 APOE APP BDNF C9orf72 CHCHD10 GBA1
4 cellular MP:0005384 10.42 APOE APP ATP13A2 BDNF C9orf72 CHCHD10
5 behavior/neurological MP:0005386 10.41 APOE APP ATP13A2 BDNF C9orf72 CHCHD10
6 no phenotypic analysis MP:0003012 10.31 APOE APP BDNF C9orf72 GRN ITM2B
7 immune system MP:0005387 10.31 APOE APP C9orf72 CHCHD10 GBA1 GRN
8 cardiovascular system MP:0005385 10.29 APOE APP ATP13A2 C9orf72 CHCHD10 GBA1
9 normal MP:0002873 10.27 APP BDNF GBA1 MAPT NOTCH3 PRNP
10 endocrine/exocrine gland MP:0005379 10.21 APOE BDNF CHCHD10 GBA1 NOTCH3 PRNP
11 muscle MP:0005369 10.15 APOE APP CHCHD10 MAPT NOTCH3 PRNP
12 skeleton MP:0005390 10.11 APOE APP CHCHD10 GBA1 NOTCH3 PRNP
13 reproductive system MP:0005389 10.1 APOE APP BDNF CHCHD10 GRN NOTCH3
14 hematopoietic system MP:0005397 10 APOE APP C9orf72 GBA1 GRN MAPT
15 vision/eye MP:0005391 9.97 APOE APP BDNF GRN MAPT NOTCH3
16 mortality/aging MP:0010768 9.83 APOE APP BDNF C9orf72 CHCHD10 GBA1
17 taste/olfaction MP:0005394 9.56 APOE BDNF MAPT SNCA
18 integument MP:0010771 9.44 APOE APP BDNF C9orf72 GBA1 GRN

Drugs & Therapeutics for Dementia

Drugs for Dementia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 549)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
2
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
3
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
4
Mirabegron Approved Phase 4 223673-61-8 18319735 9865528
5
Huperzine A Approved, Experimental Phase 4 102518-79-6
6
Quinidine Approved, Investigational Phase 4 56-54-2, 130-95-0, 804-63-7 1065 441074 3034034 8549
7
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
8
Dextromethorphan Approved Phase 4 125-71-3 5362449 5360696
9
Acetaminophen Approved Phase 4 103-90-2 1983
10
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
11
Olanzapine Approved, Investigational Phase 4 132539-06-1 135398745 4585
12
Mecobalamin Approved, Investigational Phase 4 13422-55-4
13
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
14
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
15
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
16
Zidovudine Approved Phase 4 30516-87-1 35370
17
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
18
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
19
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
20
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
21
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7, 53152-21-9 644073 40400
22
Warfarin Approved Phase 4 81-81-2, 129-06-6 54678486
23
Dabigatran Approved, Investigational Phase 4 211914-51-1 216210
24
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
25
Atropine Approved, Vet_approved Phase 4 101-31-5, 5908-99-6, 51-55-8 3661 154417 174174
26
Dextroamphetamine Approved, Illicit, Investigational Phase 4 51-64-9, 300-62-9 5826 3007
27
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
28
Nevirapine Approved Phase 4 129618-40-2 4463
29
Atorvastatin Approved Phase 4 134523-00-5 60823
30
Pimavanserin Approved, Investigational Phase 4 706779-91-1 10071196
31
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
32
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
33
Zoledronic acid Approved Phase 4 118072-93-8 68740
34
Prazosin Approved Phase 4 19216-56-9 4893
35
Iodine Approved, Investigational Phase 4 7553-56-2 807
36
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
37
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
38
Cobicistat Approved Phase 4 1004316-88-4 24950485 25151504
39
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
40
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 24892734 16212801 44176380
41
Ubidecarenone Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
42
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354
43
Choline Approved, Nutraceutical Phase 4 62-49-7 305
44
Cobalamin Experimental Phase 4 13408-78-1 6857388
45
Cerebrolysin Experimental Phase 4 12656-61-0
46
Tenofovir Experimental, Investigational Phase 4 147127-20-6, 202138-50-9 464205 6398764
47
Corticosterone Experimental Phase 4 50-22-6 5753
48
Cadexomer iodine Experimental Phase 4 94820-09-4
49 Hypnotics and Sedatives Phase 4
50 Adrenergic Agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 2073)
# Name Status NCT ID Phase Drugs
1 Monitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title) Unknown status NCT04117178 Phase 4 Donepezil;Memantine
2 Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer's Disease, Vascular Dementia and Mixed Vascular and Alzheimer's Dementia Unknown status NCT00229333 Phase 4 Escitalopram
3 Memantine Treatment in Alzheimer's Disease Patients Stratified With Behavioral and Psychological Symptoms of Dementia (BPSD) Symptoms and Cognitive Severity: A Multi-center, Open-label, Parallel-group and Prospective Clinical Study Unknown status NCT03168997 Phase 4 Memantine Hydrochloride
4 A Randomised Placebo Controlled Trial of a Cholinesterase Inhibitor in the Management of Agitation in Dementia That is Unresponsive to a Psychological Intervention Unknown status NCT00142324 Phase 4 Donepezil
5 Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dementia/MCI) Unknown status NCT00306124 Phase 4 Levodopa
6 Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia: A Multi-center, Randomized, Open-label, Pilot Study Unknown status NCT03441516 Phase 4 Alfoatirin® Tab. + Aripezil® Tab.;Aripezil® Tab.
7 A Multicenter, Randomized, Open-label, Prospective Study to Estimate the add-on Effects of Memantine as Ebixa Oral Pump on Language in Moderate to Severe Alzheimer's Disease Patients Already Receiving Donepezil. Unknown status NCT01849042 Phase 4 Ebixa;donepezil
8 The Role of Ketamine in Preventing Cognitive Dysfunctions in Postoperative Period of Cardiac Surgery Unknown status NCT02782429 Phase 4 Ketamine
9 Higher Neural and Cognitive Changes Following Anticholinergic Versus Beta 3 Agonist Versus Placebo Treatments in Female Patients With Overactive Bladder: a Multicenter Randomized Controlled Pilot Trial Unknown status NCT03817931 Phase 4 Anticholinergic;Beta-3 Agonists, Adrenergic
10 Huperzine-A for Cognitive Dysfunction and Functional Status in Schizophrenia Unknown status NCT01012830 Phase 4 Huperzine A
11 Phase IV Study of General Clinical Research Center Of the Jinan Mental Hospital(TAIWAN) Unknown status NCT00626613 Phase 4 Risperdal,reminyl
12 Effect of the Stage Specific Cognitive Intervention Program on Functional Cortical Activation in Alzheimer's Disease Unknown status NCT01329601 Phase 4
13 Long-term Outcome Followed-up of the Cognitive Disorders After General Anesthesia Unknown status NCT01184638 Phase 4 Sevoflurane;Propofol
14 A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
15 Randomized Comparison of Monotherapy (Risperidone, Quetiapine, or Olanzapine) Versus Combination Therapy (Risperidone, Quetiapine, or Olanzapine + Divalproex)in the Management of Dementia With Agitation: A Pilot Comparison of Two Standard Therapies Completed NCT00208819 Phase 4 risperidone;quetiapine;olanzapine;divalproex
16 A Randomised, Double-blind, Placebo-controlled, 6-month Study of the Efficacy and Safety of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed NCT00855686 Phase 4 Memantine;Placebo
17 Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) Completed NCT00385684 Phase 4 hydrocodone/APAP w placebo PRN;hydrocodone/APAP;placebo with hydrocodone/APAP PRN
18 Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Completed NCT00847860 Phase 4 Cilostazol;Aspirin
19 An Open Label Study on the Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Completed NCT00165763 Phase 4 donepezil hydrochloride (Aricept)
20 A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Completed NCT00947531 Phase 4 Cerebrolysin;0.9% Saline Solution
21 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
22 Interventional, Open-label Study of Flexible Doses of Vortioxetine on Depressive Symptoms in Patients With Major Depressive Disorder and Early Dementia Completed NCT04294654 Phase 4 Vortioxetine
23 Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study Completed NCT00495820 Phase 4 Methylphenidate
24 Study on the Efficacy of Speed-Feedback Therapy for Elderly People With Dementia: a Randomized Controlled Trial Completed NCT00450047 Phase 4
25 Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - an Open Study. Completed NCT00433121 Phase 4 Risperidone;Olanzapine;Haloperidole;Quetiapin;Escitalopram;Citalopram;Sertralin
26 Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and MMSE Range 5 - 18 Completed NCT02553928 Phase 4 Memantine (once daily);Memantine (twice daily)
27 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Donepezil Hydrochloride (E2020) in Patients With Dementia Associated With Cerebrovascular Disease Completed NCT02660983 Phase 4 Donepezil hydrochloride;Donepezil matching placebo
28 A Randomized Placebo-controlled Trial Evaluating the Effect of Melatonin on Sleep Quality in Patients With Dementia Completed NCT03066518 Phase 4 Melatonin 5 mg
29 Competence Network - Dementia (BMBF) "Pharmacological and Psychosocial Treatment" (Modul E.2) Part II: The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease Completed NCT01921972 Phase 4 Galantamine CR;Memantine;Placebo
30 A Pilot, Multiple Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Use of Methylphenidate for Cognitive and Behavioral Symptoms in Mild Cognitive Impairment and Dementia Completed NCT03811847 Phase 4 Methylphenidate Extended Release Oral Capsule
31 A 24-week Prospective, Double Blind, Randomized, Placebo-controlled Pilot Study of 9 mg/Day Rivastigmine in Patients With Vascular Cognitive Impairment Not Dementia to Evaluate Efficacy, Safety and Tolerability in Asian Patients Completed NCT00669344 Phase 4 Exelon (rivastigmine);Placebo
32 Efficacy of Pain Treatment on Depression in Patients With Dementia. A Randomized Clinical Trial. Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
33 The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life Completed NCT00814658 Phase 4 Galantamine;Nimodipine;Placebo
34 Corticolimbic Degeneration and Treatment of Dementia Completed NCT00768261 Phase 4 Memantine (Namenda®);Donepezil (Aricept®)
35 Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF Trial) Completed NCT03061006 Phase 4 Dabigatran Etexilate;Warfarin
36 Phase IV-An Open-Label Prospective Study of Memantine in Institutionalized Patients With Severe Alzheimer's Disease and Significant Behavioural and Psychological Symptoms of Dementia Completed NCT00401167 Phase 4 memantine
37 Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) Completed NCT00043849 Phase 4 Quetiapine
38 Donepezil for Dementia in Parkinson's Disease: A Randomized, Double Blinded Placebo Controlled Crossover Trial Completed NCT00030979 Phase 4 Donepezil
39 The Effects of the Rivastigmine Patch on Attention and Behavior in Parkinson's Disease With Dementia (PDD) Completed NCT00988117 Phase 4 Rivastigmine Patch 9.5 cm2
40 A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB) Completed NCT02345213 Phase 4 E2020;Placebo
41 The Role of Methycobalamin in Early Dementia Patients With Vitamin B12 Deficiency and Hyperhomocysteinaemia. Completed NCT00165711 Phase 4 Mecobalamin
42 An Open Label, Single-Center Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies Completed NCT01023672 Phase 4 Armodafinil
43 Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - a 24 Weeks Double Blind RCT. Completed NCT00594269 Phase 4 Risperidone;Escitalopram;Citalopram;Sertraline;Paroxetine
44 Can Oral Vitamin B12 and Folate Supplementation Preserve Cognitive Function of Patients With Early Dementia? Completed NCT00164970 Phase 4
45 A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44 Completed NCT00948766 Phase 4 Rivastigmine 4.6 mg/24 h (5 cm^2);Rivastigmine 9.5 mg/24 h (10 cm^2);Rivastigmine 13.3 mg/24 h (15 cm^2);Placebo
46 Rivastigmine Patch Effect on the Post-operative Delirium Limited to Femur Neck Fracture Operation in Patients at Risk of Dementia. Completed NCT02413554 Phase 4 Rivastigmine patch
47 A Prospective, Open-labeled, Multicenter Study of Galantamine on the Attention and Frontal Function of the Patients With Dementia of Alzheimer Type Completed NCT00216515 Phase 4 galantamine hydrobromide
48 An Open-Label Exploratory Study With Memantine: Assessment of Selected Measures of Volumetric MRI and Cognition in Patients With Moderate Dementia of the Alzheimer's Type Completed NCT00334906 Phase 4 memantine HCl
49 Pragmatic Randomized Control Trial of Memantine For Agitation In Dementia Completed NCT00371059 Phase 4 Memantine;Placebo
50 Efficacy and Tolerance of EGb 761® 120mg Two Times a Day on Dementia of Alzheimer Type's Onset in Patients Suffering From Memory Complaints. A Randomised, Double-blind, Multicentre, Parallel Groups, Placebo Controlled Phase IIIb/IV Study in Elderly Over 70 Completed NCT00276510 Phase 4 EGb 761® (Tanakan®)

Search NIH Clinical Center for Dementia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Citalopram
Citalopram hydrobromide
Prochlorperazine
Prochlorperazine Edisylate Salt
Prochlorperazine Maleate
Risperidone

Cochrane evidence based reviews: dementia

Genetic Tests for Dementia

Genetic tests related to Dementia:

# Genetic test Affiliating Genes
1 Dementia 28

Anatomical Context for Dementia

Organs/tissues related to Dementia:

MalaCards : Brain, Temporal Lobe, Bone Marrow, Prefrontal Cortex, Globus Pallidus, Heart, Cortex

Publications for Dementia

Articles related to Dementia:

(show top 50) (show all 45100)
# Title Authors PMID Year
1
Factors associated with formal and informal resource utilization in nursing home patients with and without dementia: cross-sectional analyses from the COSMOS trial. 41
36324159 2022
2
Effect of an 18-Month Meditation Training on Regional Brain Volume and Perfusion in Older Adults: The Age-Well Randomized Clinical Trial. 41
36215061 2022
3
Effect of Exercise Training or Complex Mental and Social Activities on Cognitive Function in Adults With Chronic Stroke: A Randomized Clinical Trial. 41
36227593 2022
4
Diabetes synergistically exacerbates poststroke dementia and tau abnormality in brain. 53 62
20398714 2010
5
Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. 53 62
20522869 2010
6
The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. 53 62
20403962 2010
7
Inclusion body myopathy, Paget's disease of the bone and fronto-temporal dementia: a disorder of autophagy. 53 62
20410287 2010
8
Odor identification impairment in carriers of ApoE-varepsilon4 is independent of clinical dementia. 53 62
18619712 2010
9
Donepezil, an acetylcholinesterase inhibitor against Alzheimer's dementia, promotes angiogenesis in an ischemic hindlimb model. 53 62
19962381 2010
10
A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. 53 62
19951274 2010
11
Will testing for apolipoprotein E assist in tailoring dementia risk reduction? A review. 53 62
19720080 2010
12
alpha-Synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. 53 62
19747426 2010
13
Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. 53 62
20174468 2010
14
Intrathecal IgG synthesis in patients with alterations in the neurochemical dementia diagnostics. 53 62
20308786 2010
15
The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. 53 62
20157249 2010
16
BRI2 homodimerizes with the involvement of intermolecular disulfide bonds. 53 62
18440095 2010
17
Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia. 53 62
20068209 2010
18
Total and phosphorylated tau protein as biological markers of Alzheimer's disease. 53 62
19853650 2010
19
Differences between clinical subspecialties in the outpatient evaluation and treatment of dementia in an academic medical center. 53 62
20110698 2010
20
Positron emission tomography in at risk patients and in the progression of mild cognitive impairment to Alzheimer's disease. 53 62
20061645 2010
21
Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis. 53 62
20129321 2010
22
[Frontotemporal dementia in association with a family history of dementia and ApoE polymorphism]. 53 62
19629426 2010
23
Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. 53 62
19858078 2009
24
Lewy body variant of Alzheimer's disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and alpha-synuclein in medial temporal lobe. 53 62
20024519 2009
25
New laboratory markers in diagnosis of alzheimer dementia. 53 62
19589198 2009
26
Decreased serum brain-derived neurotrophic factor levels in elderly korean with dementia. 53 62
20140129 2009
27
The morbid anatomy of dementia in Parkinson's disease. 53 62
19820956 2009
28
Conformational changes specific for pseudophosphorylation at serine 262 selectively impair binding of tau to microtubules. 53 62
19769346 2009
29
The effect of amino acid substitution in the imperfect repeat sequences of alpha-synuclein on fibrillation. 53 62
19596443 2009
30
Characterization of hydrophobic residue requirements for alpha-synuclein fibrillization. 53 62
19722699 2009
31
Cognitive and neuropsychiatric profile of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. 53 62
19935145 2009
32
Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. 53 62
19705471 2009
33
Serotonergic system genes in psychosis of Alzheimer dementia: meta-analysis. 53 62
19910872 2009
34
TDP-43 in ubiquitinated inclusions in the inferior olives in frontotemporal lobar degeneration and in other neurodegenerative diseases: a degenerative process distinct from normal ageing. 53 62
19330339 2009
35
Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). 53 62
19524111 2009
36
Depression and psychiatric symptoms preceding onset of dementia in a family with early-onset Alzheimer disease with a novel PSEN1 mutation. 53 62
19280102 2009
37
Paraoxonase activity and dementia. 53 62
19268306 2009
38
Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies? 53 62
19711118 2009
39
Mitochondrial disorders, cognitive impairment and dementia. 53 62
19268975 2009
40
Recent insights into the molecular genetics of dementia. 53 62
19640594 2009
41
Cognitive activities delay onset of memory decline in persons who develop dementia. 53 62
19652139 2009
42
Current concepts in vascular cognitive impairment and pharmacotherapeutic implications. 53 62
19584390 2009
43
Molecular mechanisms of alpha-synuclein neurodegeneration. 53 62
18955133 2009
44
Association between BDNF Val66Met polymorphism and Alzheimer disease, dementia with Lewy bodies, and Pick disease. 53 62
19812463 2009
45
[Genetic basis for dementia]. 53 62
19507496 2009
46
Hyperphosphorylated tau in the occipital cortex in aged nondemented subjects. 53 62
19458543 2009
47
Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies. 53 62
19303930 2009
48
[The genetics of dementias. Part 1: Molecular basis of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)]. 53 62
19535823 2009
49
Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia. 53 62
19380227 2009
50
Association of glucocerebrosidase mutations with dementia with lewy bodies. 53 62
19433657 2009

Variations for Dementia

ClinVar genetic disease variations for Dementia:

5 (show all 13)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PSEN1 NM_000021.4(PSEN1):c.314T>G (p.Phe105Cys) SNV Pathogenic
374134 rs1057518919 GRCh37: 14:73637731-73637731
GRCh38: 14:73171023-73171023
2 MAPT NM_001377265.1(MAPT):c.2091+16C>T SNV Pathogenic
98222 rs63751011 GRCh37: 17:44087784-44087784
GRCh38: 17:46010418-46010418
3 PSEN1 NM_000021.4(PSEN1):c.709T>C (p.Phe237Leu) SNV Likely Pathogenic
98072 rs63750858 GRCh37: 14:73659512-73659512
GRCh38: 14:73192804-73192804
4 PSEN1 NM_000021.4(PSEN1):c.791C>T (p.Pro264Leu) SNV Likely Pathogenic
98080 rs63750301 GRCh37: 14:73664760-73664760
GRCh38: 14:73198052-73198052
5 SLC25A24 NM_013386.5(SLC25A24):c.758G>C (p.Gly253Ala) SNV Likely Pathogenic
692155 rs1571285932 GRCh37: 1:108697669-108697669
GRCh38: 1:108155047-108155047
6 LOC106627981, GBA1 NM_000157.4(GBA1):c.1093G>A (p.Glu365Lys) SNV Risk Factor
199044 rs2230288 GRCh37: 1:155206167-155206167
GRCh38: 1:155236376-155236376
7 TYROBP NM_003332.4(TYROBP):c.94G>A (p.Asp32Asn) SNV Uncertain Significance
374122 rs758290972 GRCh37: 19:36398632-36398632
GRCh38: 19:35907730-35907730
8 MRE11 NM_005591.4(MRE11):c.1727G>A (p.Arg576Gln) SNV Uncertain Significance
127974 rs139461096 GRCh37: 11:94180441-94180441
GRCh38: 11:94447275-94447275
9 SLC25A24 NM_013386.5(SLC25A24):c.1273C>A (p.Leu425Met) SNV Uncertain Significance
692156 rs780069314 GRCh37: 1:108679436-108679436
GRCh38: 1:108136814-108136814
10 MRE11 NM_005591.4(MRE11):c.229G>A (p.Glu77Lys) SNV Uncertain Significance
481777 rs779269083 GRCh37: 11:94219175-94219175
GRCh38: 11:94486009-94486009
11 MT-ND4 NC_012920.1:m.11815C>G SNV Uncertain Significance
370053 rs879025367 GRCh37: MT:11815-11815
GRCh38: MT:11815-11815
12 MT-ND4 NC_012920.1:m.12013A>G SNV Uncertain Significance
370056 rs1057516067 GRCh37: MT:12013-12013
GRCh38: MT:12013-12013
13 MT-ND4 NC_012920.1:m.12018C>G SNV Uncertain Significance
370057 rs1057516068 GRCh37: MT:12018-12018
GRCh38: MT:12018-12018

Expression for Dementia

Search GEO for disease gene expression data for Dementia.

Pathways for Dementia

GO Terms for Dementia

Cellular components related to Dementia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.41 APOE APP BDNF C9orf72 GRN ITM2B
2 dendrite GO:0030425 10.22 APOE BDNF C9orf72 MAPT PRNP PSEN1
3 endosome GO:0005768 10.19 PSEN1 ITM2B GRN C9orf72 ATP13A2 APP
4 membrane raft GO:0045121 10.13 APP MAPT PRNP PSEN1 PSEN2
5 synaptic vesicle GO:0008021 10.1 PSEN2 PSEN1 BDNF APP
6 axon GO:0030424 10.1 SNCA PSEN1 MAPT C9orf72 BDNF APP
7 postsynapse GO:0098794 10.05 SNCA PSEN1 PRNP C9orf72
8 dendritic shaft GO:0043198 9.93 PSEN2 PSEN1 APP
9 gamma-secretase complex GO:0070765 9.83 PSEN2 PSEN1
10 inclusion body GO:0016234 9.8 SNCB SNCA PRNP
11 ciliary rootlet GO:0035253 9.73 PSEN2 PSEN1 APP
12 growth cone GO:0030426 9.65 SNCA PSEN2 PSEN1 MAPT C9orf72 APP
13 main axon GO:0044304 9.63 APP C9orf72 MAPT
14 neuronal cell body GO:0043025 9.53 SNCB SNCA SERPINI1 PSEN2 PSEN1 MAPT

Biological processes related to Dementia according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 Notch signaling pathway GO:0007219 10.22 PSEN2 PSEN1 NOTCH3 APP
2 autophagy GO:0006914 10.21 VCP PSEN1 GBA1 C9orf72 ATP13A2
3 neuron projection development GO:0031175 10.18 MAPT GBA1 APP APOE
4 memory GO:0007613 10.18 TREM2 PSEN1 MAPT BDNF
5 response to oxidative stress GO:0006979 10.17 APOE APP PRNP PSEN1
6 negative regulation of neuron death GO:1901215 10.14 SNCA GBA1 ATP13A2
7 neuron apoptotic process GO:0051402 10.13 SNCB SNCA PSEN1 GBA1 APP
8 cellular response to amyloid-beta GO:1904646 10.1 APP PRNP PSEN1 TREM2
9 learning or memory GO:0007611 10.09 APP MAPT PRNP PSEN1
10 cellular response to copper ion GO:0071280 10.08 SNCA PRNP APP
11 forebrain development GO:0030900 10.08 TYROBP PSEN1 NOTCH3 APP
12 positive regulation of neuron death GO:1901216 10.08 TYROBP SNCA PRNP MAPT
13 amyloid fibril formation GO:1990000 10.07 APP MAPT SNCA
14 regulation of peptidyl-tyrosine phosphorylation GO:0050730 10.06 TREM2 PRNP APP
15 microglial cell activation GO:0001774 10.06 TREM2 SNCA MAPT APP
16 lipid homeostasis GO:0055088 10.04 TREM2 ATP13A2 APOE
17 regulation of protein metabolic process GO:0051246 10 GBA1 APP APOE
18 regulation of protein metabolic process GO:0032268 10 GBA1
19 neuron projection maintenance GO:1990535 9.99 PSEN1 PRNP APP
20 cellular response to manganese ion GO:0071287 9.97 ATP13A2 APP
21 amyloid-beta formation GO:0034205 9.97 PSEN2 PSEN1
22 Notch receptor processing GO:0007220 9.96 PSEN2 PSEN1
23 microglial cell proliferation GO:0061518 9.96 GBA1 TREM2
24 synapse organization GO:0050808 9.96 SNCB SNCA PSEN1 MAPT APP
25 positive regulation of amyloid-beta clearance GO:1900223 9.95 APOE TREM2
26 autophagosome organization GO:1905037 9.94 GBA1 ATP13A2
27 positive regulation of macrophage fusion GO:0034241 9.93 TYROBP TREM2
28 regulation of lysosomal protein catabolic process GO:1905165 9.91 GBA1 ATP13A2
29 microglial cell activation involved in immune response GO:0002282 9.88 GRN TREM2 TYROBP
30 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.87 PSEN1 APP
31 negative regulation of protein metabolic process GO:0051248 9.85 GBA1 APOE
32 positive regulation of amyloid fibril formation GO:1905908 9.85 PSEN1 APP APOE
33 astrocyte activation involved in immune response GO:0002265 9.8 PSEN1 GRN APP
34 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.79 PSEN1 APP
35 astrocyte activation GO:0048143 9.76 APP MAPT PSEN1 TREM2
36 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.64 PSEN1 APP
37 negative regulation of long-term synaptic potentiation GO:1900272 9.56 TYROBP PRNP APP APOE
38 negative regulation of neuron apoptotic process GO:0043524 9.47 SNCB SNCA PSEN1 GRN GBA1 BDNF

Molecular functions related to Dementia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.97 VCP TREM2 SNCA ATP13A2 APOE
2 amyloid-beta binding GO:0001540 9.76 TREM2 PRNP ITM2B APOE
3 aspartic endopeptidase activity, intramembrane cleaving GO:0042500 9.67 PSEN2 PSEN1
4 cupric ion binding GO:1903135 9.56 PRNP ATP13A2
5 lipoprotein particle binding GO:0071813 9.43 TREM2 MAPT APOE
6 cuprous ion binding GO:1903136 9.1 SNCB SNCA PRNP

Sources for Dementia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....